DJIA 17,776.12 -200.19 -1.11%
NASDAQ 4,900.89 -46.56 -0.94%
S&P 500 2,067.89 -18.35 -0.88%
market minute promo

Ophthotec (NASDAQ: OPHT)

46.53 -1.47 (-3.06%)

Quote as of

Extended Hours: $46.53 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

OPHT $46.53 -3.06%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $47.86
Previous Close $48.00
Daily Range $46.38 - $48.34
52-Week Range $30.13 - $58.29
Market Cap $1.6B
P/E Ratio -16.27
Dividend (Yield) $0.00 (0.0%)
Volume 258,918
Average Daily Volume 291,009
Current FY EPS -$2.98

Sector

Industry

Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website: http://www.ophthotechinc.com/

News & Commentary

3 Little-Known Biotechs Working On Potential Blockbusters

These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.

3 Little-Known Stocks I'm Glad I Bought

Ophthotech Corp, Portola Pharmaceuticals Inc., and Insys Therapeutics Inc., have been top performers this past year.

2 Tiny Biotechs That Could Have Blockbuster Opportunity

Got risk tolerance? Check out these two small cap biotechs with huge potential.

Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog

Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript

Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog

Can These Three BioTech Companies Make It Big?

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Benzinga's Top Initiations

Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog

See More OPHT News...